Jade Biosciences, Inc.
PrivateLast Round
Follow-on Offering
Jun 5, 2026
Est. Valuation
$1.04B
Total Funding Raised
$507.7M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Jade Biosciences, Inc. (formerly Aerovate Therapeutics, Inc.) is a biotechnology company that develops biologic therapies for autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Jade Biosciences, Inc. Comparables
Compare Jade Biosciences, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Jade Biosciences | 100% | |
| Vera Therapeutics | 81% | |
| Climb Bio, Inc. | 80% |
Jade Biosciences, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jun 5, 2026 | ||||
| Private Placement | Dec 15, 2025 | ||||
| PIPE | Oct 7, 2025 | ||||
| M&A | Apr 28, 2025 | ||||
| Convertible Debt | Oct 24, 2024 | ||||
Follow-on Offering | Apr 1, 2024 |
Jade Biosciences, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | M&A |
| Deerfield Management | M&A |
| Janus Henderson Group | PIPE |
| RA Capital Advisors | Series A |
| RA Capital Management | M&A, PIPE, Series A, Convertible Debt, Seed |
| Fairmount Funds Management | PIPE, Convertible Debt, M&A |
| BB Biotech | Private Placement |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 5, 2026
$173M raised in follow-on offering.
- Dec 15, 2025
$45M round led by BB Biotech.
Jade Biosciences, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Jade Biosciences, Inc.'s valuation, stock price, and market status.
Is Jade Biosciences, Inc. a public or private company?
Jade Biosciences, Inc. is a private company.
What is the current stock price of Jade Biosciences, Inc.?
Jade Biosciences, Inc. is a private company, so its shares have no public market price. Caplight tracks Jade Biosciences, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Jade Biosciences, Inc. worth (valuation)?
Jade Biosciences, Inc.'s valuation is estimated at $1.0B based on funding round data.
Can I buy Jade Biosciences, Inc. stock?
Jade Biosciences, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Jade Biosciences, Inc.'s last funding round?
Jade Biosciences, Inc.'s most recent funding round was Follow-on Offering on June 5, 2026.
Who are the main investors in Jade Biosciences, Inc.?
Key investors in Jade Biosciences, Inc. include RA Capital Management, Fairmount Funds Management, BB Biotech, Venrock, Sofinnova Investments.
Will Jade Biosciences, Inc. IPO soon?
No public IPO plans have been announced for Jade Biosciences, Inc..
How can I track Jade Biosciences, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Jade Biosciences, Inc.'s shares on secondary markets.